Autres langues Argenica Therapeutics Limited

Actions

AGN

AU0000150328

Marché Fermé - Australian S.E. Autres places de cotation 07:36:54 01/05/2024			Varia. 5j.	Varia. 1 janv.
0,58 ^AUD	-0,85%		+6,42%	+13,73%

16/04	ARGENICA THERAPEUTICS LIMITED : Euroz Hartleys reste à l'achat	ZM
28/03	Argenica Therapeutics administre le premier patient dans le cadre de son essai de phase deux sur les accidents vasculaires cérébraux ; les actions augmentent de 14 %.	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Argenica Therapeutics Raises AU$12 Million via Placement	12/04
Argenica Therapeutics Doses First Batch of Patients for Phase Two Stroke Trial	10/04
Argenica Therapeutics Doses First Patient in Phase Two Stroke Trial; Shares Rally 14%	28/03
FDA Grants Argenica Rare Pediatric Disease Designation for Hypoxic Ischaemic Encephalopathy Treatment; Shares Up 16%	25/03
Argenica Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02
Argenica Therapeutics Concludes Manufacturing, Release Testing for Stroke Drug; Shares Rise 3%	12/02
Argenica Therapeutics On Track for First Patient Dosing in Phase 2 ARG-007 Trial in Q1 2024	14/12
AusBiotech energised by new Board appointments	11/12
Argenica Therapeutics Appoints Nonexecutive Chair	30/11
Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023	29/11
Argenica Therapeutics Secures US FDA Orphan Drug Designation for Neurological Medication	15/11
Argenica Therapeutics Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023	13/11
Argenica Therapeutics Limited Announces the Resignation of Dr. Samantha South as Executive Director Effective 30 November 2023	27/10/23
Argenica Therapeutics' Drug Candidate Reduces Brain Injury in Hypoxic-Ischemic Encephalopathy Preclinical Model	18/10/23
Argenica Therapeutics Secures Ethics Approval for Phase 2 Stroke Trial	12/09/23
Argenica Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23/08/23
Preclinical Data Shows Argenica Therapeutics' ARG-007 Able to Mitigate Neurodegenerative Disorders	02/08/23
Argenica Therapeutics Files Ethics Application for Phase Two Stroke Trial	19/07/23
Argenica Therapeutics Validates Efficacy of Neuroprotective Drug in Preclinical Trial	23/06/23
22,625,752 Ordinary Shares of Argenica Therapeutics Limited are subject to a Lock-Up Agreement Ending on 11-JUN-2023.	11/06/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Argenica Therapeutics Limited

Actions

AGN

AU0000150328

Autres langues

Filtres